Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fengshigutong + imrecoxib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fengshigutong + imrecoxib is a combination therapy investigated for the treatment of active ankylosing spondylitis. It consists of Fengshigutong Capsule (FSGTC), a traditional Chinese herbal medicine containing seven specific herbs (Aconiti Radix Cocta, Aconiti Kusnezoffii Radix Cocta, Carthami Flos, Glycyrrhizae Radix Et Rhizoma, Chaenomelis Fructus, Mume Fructus, and Ephedrae Herba), and imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The combination aims to enhance efficacy in reducing disease activity (as measured by ASDAS-CRP) while potentially improving gastrointestinal tolerability compared to NSAID monotherapy. The therapy was evaluated in a Phase 4 clinical trial led by the Third Affiliated Hospital of Sun Yat-sen University, which demonstrated superior disease control compared to imrecoxib alone.
- Brand names
- Fengshigutong CapsuleImrecoxib
- Other names
- FSGTC + imrecoxibFengshigutong Capsule plus Imrecoxib
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Fengshigutong + imrecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fengshigutong + imrecoxib.